LEXINGTON, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present a general corporate overview at the Therapeutic Area Partnerships (TAP) meeting scheduled to take place November 19-21, 2014 in Boston, MA. Dr. Brady will present at 10:50AM ET as part of the "Top Projects to Watch" within the anti-inflammatory/autoimmune industry.
Details of the presentation are as follows:
|Therapeutic Area Partnerships|
|Date:||Thursday, November 20, 2014|
|Time:||10:50 a.m. ET|
|Place:||The Hyatt Regency (Boston, MA)|
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to file Investigational New Drug applications for clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com
About the Therapeutic Area Partnerships (TAP)
A meeting for the sharpest minds in biopharma. Since its launch eight years ago, TAP has come to be regarded as the industry's premier biopharmaceutical partnering event. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in: Oncology, Cardiovascular, Neuroscience, Infectious Diseases, Anti-Inflammatory/Autoimmune Diseases, Advanced Therapies (Cellular and Gene Therapies, Rare Diseases and other high value and niche areas).
Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry's most productive events.
CONTACT: Investor Contact: David Burke The Ruth Group Tel: +1 646-536-7009 email@example.comSource:Aldeyra Therapeutics